Testosterone vs NandroloneDECA Comparison — QSC Peptides Research Reference

The Core Difference — 5α-Reduction Product

This is the single most important pharmacological distinction between testosterone and nandrolone. 5α-reductase converts testosterone to DHT (3–5× higher AR affinity — amplifies androgenicity in skin, prostate, scalp). The same enzyme converts nandrolone to DHN (5α-dihydronandrolone) — which has lower AR affinity than nandrolone itself. This 5α-reduction uniquely reduces nandrolone's androgenicity in 5α-reductase-rich tissues, explaining the low androgenic ratio of 37.

Aromatization Profiles

Testosterone aromatizes readily to estradiol (E2) via CYP19A1 in adipose tissue and muscle. Nandrolone aromatizes minimally — approximately 20% of testosterone's aromatization rate — and to estrone (E1, a weaker estrogen) rather than estradiol. Research requiring estrogen control studies should note this fundamental difference.

Progestin Activity — Unique to Nandrolone

Testosterone has no progestin receptor (PR) activity. Nandrolone binds PR at ~20% of progesterone's affinity — making it a weak progestin. In research on AAS effects in tissues expressing both AR and PR (uterus, mammary tissue, certain CNS regions), nandrolone offers combined AR/PR activation while testosterone provides isolated AR activation.

When to Use Each

• Use Testosterone when studying the full androgen/estrogen profile from a single compound — pure AR reference, DHT-mediated androgenicity, or aromatization research
• Use Nandrolone (DECA) when higher anabolic:androgenic selectivity is needed, when AR/PR co-activation is the research endpoint, or when collagen synthesis and joint tissue effects are of interest